{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:32:57Z","timestamp":1759941177753},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.clinthera.2015.10.006","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T00:22:31Z","timestamp":1446682951000},"page":"2772-2779","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetics of a New Orally Disintegrating Tablet Formulation of Aripiprazole 15 mg Administered Without Water in Healthy Middle-aged Korean Subjects"],"prefix":"10.1016","volume":"37","clinical-trial-number":[{"clinical-trial-number":"kct0001677","registry":"10.18810\/cris"}],"author":[{"given":"Yunjeong","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Young","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Chul","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Gul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.10.006_bib1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/oxfordjournals.schbul.a007017","article-title":"Schizophrenia, consciousness, and the self","volume":"29","author":"Sass","year":"2003","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.clinthera.2015.10.006_bib2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fnbeh.2014.00171","article-title":"Bridging disparate symptoms of schizophrenia: a triple network dysfunction theory","volume":"8","author":"Nekovarova","year":"2014","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.clinthera.2015.10.006_bib3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/ajhp\/57.3.238","article-title":"Atypical antipsychotic agents: a critical review","volume":"57","author":"Worrel","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2015.10.006_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2174\/0929867024606939","article-title":"Schizophrenia: genesis, receptorology and current therapeutics","volume":"9","author":"Capuano","year":"2002","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.clinthera.2015.10.006_bib5","first-page":"1","article-title":"Top 100 selling drugs of 2013","author":"Brooks","year":"2014","journal-title":"Medscape Medical News"},{"key":"10.1016\/j.clinthera.2015.10.006_bib6","unstructured":"Otsuka Pharmaceutical Co. L. Full prescribing information-Abilify (Aripiprazole). (www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022192s007lbl.pdf), 2014."},{"key":"10.1016\/j.clinthera.2015.10.006_bib7","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1002\/jssc.201000457","article-title":"A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies","volume":"33","author":"Akamine","year":"2010","journal-title":"J Sep Sci"},{"key":"10.1016\/j.clinthera.2015.10.006_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2015.10.006_bib9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1527-3458.2004.tb00030.x","article-title":"Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology","volume":"10","author":"Davies","year":"2004","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.clinthera.2015.10.006_bib10","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder","volume":"64","author":"Swainston Harrison","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2015.10.006_bib11","unstructured":"Abilify (aripiprazole) [package insert]. Princeton, NJ: Bristol-Myers Squibb; December 2010."},{"key":"10.1016\/j.clinthera.2015.10.006_bib12","unstructured":"Otsuka Pharmaceutical Co. L. Aripiprazole Prescribing Information, 2014."},{"key":"10.1016\/j.clinthera.2015.10.006_bib13","unstructured":"Data Sheet for ABILIFYTM aripiprazole Tablets: 10 mg, 15 mg, 20 mg and 30 mg, 2015:1-38."},{"key":"10.1016\/j.clinthera.2015.10.006_bib14","unstructured":"Draft Guidance on Aripiprazole. FDA; November, 2007. (http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm082554.pdf)."},{"key":"10.1016\/j.clinthera.2015.10.006_bib15","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jchromb.2005.06.023","article-title":"Development and validation of an LC-MS\/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma","volume":"822","author":"Kubo","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2015.10.006_bib16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.curtheres.2006.08.003","article-title":"Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: a prospective, open-label, pilot study","volume":"67","author":"Zuo","year":"2006","journal-title":"Curr Ther Res"},{"key":"10.1016\/j.clinthera.2015.10.006_bib17","first-page":"CD006569","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","volume":"1","author":"Khanna","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2015.10.006_bib18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2133\/dmpk.22.358","article-title":"Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism","volume":"22","author":"Kubo","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2015.10.006_bib19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/hup.806","article-title":"Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study","volume":"21","author":"Kim","year":"2006","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.clinthera.2015.10.006_bib20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.schres.2013.06.041","article-title":"Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study","volume":"150","author":"Mallikaarjun","year":"2013","journal-title":"Schizophren Res"},{"key":"10.1016\/j.clinthera.2015.10.006_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4314\/tjpr.v8i2.44525","article-title":"Orally disintegrating tablets: a review","volume":"8","author":"Hirani","year":"2009","journal-title":"Trop J Pharmaceutical Res"},{"key":"10.1016\/j.clinthera.2015.10.006_bib22","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2015.10.006_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2015.10.006_bib24","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/JCP.0b013e31818d6b67","article-title":"Antidepressant-induced sweating alleviated by aripiprazole","volume":"28","author":"Lu","year":"2008","journal-title":"J Clin Psychopharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181501156X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181501156X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T08:03:18Z","timestamp":1567324998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181501156X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S014929181501156X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.10.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}